zoledronic acid has been researched along with 25-hydroxyvitamin d 2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anastasilakis, AD; Arsos, G; Barmpalios, G; Efstathiadou, Z; Kita, M; Litsas, I; Makrigiannaki, E; Moralidis, E; Panagiotou, A; Papatheodorou, A; Polyzos, SA; Terpos, E; Triantafillidou, E; Zafeiriadou, E | 1 |
| Carter, D; Churchill, W; Clapp, M; Reddy, P; Slovik, D; Yeh, Y | 1 |
1 trial(s) available for zoledronic acid and 25-hydroxyvitamin d 2
| Article | Year |
|---|---|
Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.
Topics: 25-Hydroxyvitamin D 2; Aged; Alkaline Phosphatase; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Calcifediol; Cohort Studies; Collagen Type I; Diphosphonates; Female; Folic Acid; Homocysteine; Humans; Imidazoles; Isoenzymes; Male; Paget Disease, Extramammary; Peptides; Pilot Projects; Time Factors; Vitamin B 12; Zoledronic Acid | 2010 |
1 other study(ies) available for zoledronic acid and 25-hydroxyvitamin d 2
| Article | Year |
|---|---|
Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.
Topics: 25-Hydroxyvitamin D 2; Aged; Bone Density Conservation Agents; Calcifediol; Calcium; Consensus; Diphosphonates; Drug Resistance; Electronic Health Records; Evidence-Based Medicine; Female; Guideline Adherence; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Zoledronic Acid | 2011 |